Supplementary Table 1. Change from baseline in BCVA at each timepoint through week 52 in the full analysis set

Timepoint (week)		**0**	**1**	**4**	**8**	**12**	**16**	**20**	**24**
SB11	Change from baseline in BCVA (letters) (SD)	-	3.3 (5.6)	5.6 (7.0)	6.5 (8.3)	7.7 (8.9)	7.9 (9.4)	8.6 (9.3)	8.5 (10.5)
	n	351	350	350	346	345	344	344	333
RBZ	Change from baseline in BCVA (letters) (SD)	-	3.7 (6.6)	6.0 (7.1)	7.4 (8.1)	8.1 (9.1)	8.7 (9.3)	8.6 (9.7)	9.3 (9.7)
	n	353	352	350	348	345	342	339	338
Timepoint (week)		**28**	**32**	**36**	**40**	**44**	**48**	**52**	
SB11	Change from baseline in BCVA (letters) (SD)	8.8 (10.9)	8.9 (10.7)	9.2 (10.7)	9.4 (11.1)	8.9 (11.9)	9.7 (11.2)	9.7 (11.4)	
	n	323	322	321	316	316	310	309	
RBZ	Change from baseline in BCVA (letters) (SD)	9.7 (10.2)	9.7 (10.4)	10.1 (11.1)	9.9 (11.6)	9.9 (11.7)	10.1 (11.9)	10.4 (11.5)	
	n	333	331	331	327	328	327	327	

Abbreviations: BCVA, best corrected visual acuity; n, number of participants with available assessment results; RBZ, ranibizumab; SD, standard deviation.

Supplementary Table 2. Change from baseline in CST at each timepoint through week 52 in the full analysis set

Timepoint (week)		**0**	**1**	**4**	**8**	**12**	**16**	**20**	**24**
SB11	Change from baseline in CST (µm) (SD)	-	-73.4 (75.8)	-105.4 (94.5)	-118.1 (98.9)	-124.9 (99.8)	-128.1 (100.8)	-129.7 (101.8)	-128.9 (99.6)
	n	351	350	350	345	344	343	343	328
RBZ	Change from baseline in CST (µm) (SD)	-	-77.0 (77.2)	-102.4 (97.3)	-116.3 (110.1)	-123.9 (111.4)	-125.7 (103.2)	-127.2 (102.8)	-127.8 (103.7)
	n	353	351	348	348	345	339	337	335
Timepoint (week)		**28**	**32**	**36**	**40**	**44**	**48**	**52**	
SB11	Change from baseline in CST (µm) (SD)	-130.7 (101.0)	-129.1 (100.3)	-128.4 (104.7)	-131.7 (104.7)	-135.0 (103.5)	-134.2 (106.1)	-133.6 (103.9)	
	n	321	320	318	316	315	307	308	
RBZ	Change from baseline in CST (µm) (SD)	-128.8 (108.2)	-130.7 (107.8)	-132.3 (108.0)	-130.4 (108.1)	-132.0 (108.8)	-131.3 (110.7)	-128.4 (116.1)	
	n	330	331	330	327	327	326	327	

Abbreviations: CST, central subfield thickness; n, number of participants with available assessment results; RBZ, ranibizumab; SD, standard deviation.

Supplementary Table 3. Proportion of participants without intra- or subretinal fluid at each timepoint through week 52 in the full analysis set

Timepoint (week)		**0**	**1**	**4**	**8**	**12**	**16**	**20**	**24**
SB11	Participant without intra or sub-retinal fluid (%)	26.2	38.3	61.7	72.3	77.0	77.6	77.6	76.2
	n	351	350	350	346	344	343	343	328
RBZ	Participant without intra or sub-retinal fluid (%)	24.6	37.5	56.3	65.5	74.2	79.4	79.8	80.9
	n	353	352	348	348	345	339	337	335
Timepoint (week)		**28**	**32**	**36**	**40**	**44**	**48**	**52**	
SB11	Participant without intra or sub-retinal fluid (%)	80.1	83.1	81.8	82.0	82.2	84.4	84.4	
	n	321	320	319	316	315	307	308	
RBZ	Participant without intra or sub-retinal fluid (%)	79.7	81.9	83.0	80.7	81.3	80.7	81.0	
	n	330	331	330	327	327	326	327	

Abbreviations: n, number of participants with available assessment results; RBZ, ranibizumab.

Supplementary Table 4. Composite Score of NEI VFQ-25 at week 0 (Baseline), 24, and 52 in the full analysis set

	Treatment	n	Mean (SD)
Week 0 (baseline)	SB11 (N=351)	288	75.7 (17.1)
	RBZ (N=353)	289	77.7 (17.1)
Week 24	SB11 (N=351)	276	79.3 (16.2)
	RBZ (N=353)	282	82.6 (14.4)
Week 52	SB11 (N=351)	261	80.5 (15.8)
	RBZ (N=353)	271	84.0 (13.9)

Abbreviations: N, total number of participants; n, number of participants with available data; RBZ, ranibizumab; SD, standard deviation.

Supplementary Table 5. Systemic serum concentrations values per timepoint in the PK analysis set

Timepoint	**Parameter**	**SB11 (N=25)** Mean (SD) [min, max]	**RBZ (N=29)** Mean (SD) [min, max]
Week 0	C_{trough} (pg/ml)	n=20	n=22
		41.2 (184.3) [0, 824]	0.0 (0.0) [0, 0]
	C_{max} (pg/ml)	n=20	n=27
		1660.9 (1265.9) [0, 4740]	1246.9 (868.0) [0, 2590]
Week 1	Conc. (pg/ml)	n=20	n=27
		687.3 (613.8) [0, 1730]	462.5 (486.0) [0, 1320]
Week 4	C_{trough} (pg/ml)	n=21	n=25
		143.8 (659.0) [0, 3020]	57.2 (286.0) [0, 1430]
	C_{max} (pg/ml)	n=22	n=24
		1371.7 (1039.9) [0, 3700]	771.2 (753.6) [0, 2210]
Week 8	C_{trough} (pg/ml)	n=22	n=25
		0.0 (0.0) [0, 0]	0.0 (0.0) [0, 0]
	C_{max} (pg/ml)	n=19	n=22
		1346.5 (1293.1) [0, 4560]	1130.2 (827.1) [0, 2780]
Week 16	C_{trough} (pg/ml)	n=24	n=26
		0.0 (0.0) [0, 0]	56.5 (288.3) [0, 1470]
	C_{max} (pg/ml)	n=22	n=23
		1688.1 (1073.9) [0, 4350]	1057.0 (710.1) [0, 2590]
Week 24	C_{trough} (pg/ml)	n=23	n=24

		0.0 (0.0) [0, 0]	0.0 (0.0) [0, 0]
	C_{max} (pg/ml)	n=23	n=23
		1952.2 (1351.2) [0, 6670]	1245.8 (712.7) [0, 2300]
Week 36	C_{trough} (pg/ml)	n=21	n=24
		0.0 (0.0) [0, 0]	0.0 (0.0) [0, 0]
	C_{max} (pg/ml)	n=20	n=21
		1947.0 (1268.2) [0, 4760]	1298.0 (511.2) [615, 2270]
Week 52	Conc. (pg/ml)	n=20	n=20
		0.0 (0.0) [0, 0]	0.0 (0.0) [0, 0]

Abbreviations: N, number of participants in the PK analysis set, n, number of participants with available data; RBZ, ranibizumab; SD, standard deviation.

Systemic exposure was measured pre-dose (trough serum concentration [C_{trough}]) and 24 to 72 hours post-dose (close to maximum serum concentration [C_{max}]).

Supplementary Figure 1. Proportion of participants with BCVA change and active CNV leakage



Abbreviations: BCVA, best corrected visual acuity (ETDRS letter score); CNV, choroidal neovascularization; ETDRS, early treatment diabetic retinopathy study; RBZ, reference ranibizumab.

A) Proportion of participants who lost fewer than 15 letters in BCVA at week 24 and 52 compared with baseline in the FAS.

B) Proportion of participants who gained 15 or more letters in BCVA at week 24 and 52 compared with baseline in the FAS.

C) Proportion of participants with active CNV leakage at week 24 and 52 in the FAS.

Supplementary Figure 2. Proportion of participants without intra-or sub-retinal fluid in the full analysis set



Week	0	1	4	8	12	16	20	24	28	32	36	40	44	48	52
SB11 (n)	351	350	350	346	344	343	343	328	321	320	319	316	315	307	308
RBZ (n)	353	352	348	348	345	339	337	335	330	331	330	327	327	326	327

Abbreviations: RBZ, reference ranibizumab.

The table reports the number of participants per timepoint. The complete list of values and participants per timepoint is reported in Supplementary Table 3.

Supplementary Figure 3. Mean systemic serum concentration through week 52 in the PK analysis set



Abbreviations: RBZ, ranibizumab.

Circles represent mean and error bars represent standard deviation at each timepoint. Serum samples for the measurements of Drug concentration were taken pre-dose (trough serum concentration [Ctrough]) and 24 to 72 hours post-dose (close to maximum serum concentration [Cmax]) at week 0, 4, 8, 16, 24 and 36, and at week 1 and 52. The lower limit of quantitation was 600 pg/mL.

The complete list of values and participants per timepoint is reported in Supplementary Table 5.